Get the Stockscreener App
15.01
1.31%
-0.20
Lyell Immunopharma Inc stock is traded at $15.01, with a volume of 116.57K.
It is down -1.31% in the last 24 hours and up +13.54% over the past month.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
See More
Previous Close:
$15.21
Open:
$15.17
24h Volume:
116.57K
Relative Volume:
0.81
Market Cap:
$350.24M
Revenue:
$31,000
Net Income/Loss:
$-246.41M
P/E Ratio:
-1.1784
EPS:
-12.7377
Net Cash Flow:
$-134.42M
1W Performance:
+6.83%
1M Performance:
+13.54%
6M Performance:
-38.86%
1Y Performance:
+53.63%
1-Day Range:
$13.81
$15.45
1-Week Range:
$13.42
$16.80
52-Week Range:
$9.025
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
15.01 | 350.24M | 31,000 | -246.41M | -134.42M | -12.74 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Needham | Buy |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Immunopharma updates pipeline strategy as cell therapy field evolves - ad-hoc-news.de
LYELLyell Immunopharma Inc Volatility & Greeks - Finviz
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet - Yahoo Finance
Form 4 Lyell Immunopharma Inc For: 1 July By Investing.com - Investing.com South Africa
Innovative Cellular Therapeutics moves 76K Lyell (LYEL) shares as broker commission - Stock Titan
Lyell Immunopharma stock maintained at Market Outperform by Citizens - Investing.com India
Lyell at H.C. Wainwright cell therapy conference: data and catalysts By Investing.com - Investing.com South Africa
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Value Benchmark - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell Microcap Value Benchmark Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell Microcap Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Dynamic Index - marketscreener.com
Lyell Immunopharma, Inc. Actuals & Estimates (NASDAQ:LYEL) - TradingView
LYEL Forecast — Price Target — Prediction for 2027 - TradingView
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
LYEL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Form 4 Lyell Immunopharma Inc For: 24 June By Investing.com - Investing.com Nigeria
Lyell Immunopharma Inc (LYEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lyell Immunopharma (LYEL) major holder transfers shares as commission - Stock Titan
Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestone - Stock Titan
Innovative Cellular Therapeutics (LYEL partner) reports 3M Lyell Immunopharma shares - Stock Titan
Lyell Immunopharma issues colorectal cancer drug safety update - MSN
Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lyell Immunopharma Inc (LYEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lyell Immunopharma Inc (LYEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lyell Immunopharma Inc (LYEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lyell Immunopharma Inc (LYEL) Institutional Confidence - TradingKey
Lyell Immunopharma Inc (LYEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lyell Immunopharma Inc (LYEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lyell Immunopharma Inc (LYEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock - Investing.com Nigeria
Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com - Investing.com South Africa
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares By Investing.com - Investing.com India
Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock - Investing.com UK
Lyell Immunopharma COO Stephen Hill sells $1,683 in shares - Investing.com UK
Lyell Immunopharma (LYEL) CEO’s 388-share tax-related stock sale detailed in Form 4 - Stock Titan
Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares - Stock Titan
Lyell Immunopharma (LYEL) COO’s 89-share sale tied to RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting - TipRanks
Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections - Stock Titan
Citizens upgrades Lyell Immunopharma stock price target on trial progress By Investing.com - Investing.com Canada
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Seely Lynn - Moomoo
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL) - Seeking Alpha
Director at Lyell Immunopharma (LYEL) receives new option grant - Stock Titan
[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity - Stock Titan
Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director granted 9,250 stock options at $13.22 - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250-share option grant - Stock Titan
Lyell Immunopharma (LYEL) director receives 9,250 options at $13.22 strike - Stock Titan
Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22 - Stock Titan
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):